Extended Data Table 1 ∣.
Characteristics of study participants, 1 November 2020–14 February 2021
| All | Missing | SGTF | Non-SGTF | SGTF prevalence | Missingness | |
|---|---|---|---|---|---|---|
| 2,245,263 (100%) | 1,098,729 (100%) | 674,539 (100%) | 471,995 (100%) | 674,539 / 1,146,534 (58.8%) | 1,098,729 / 2,245,263 (48.9%) | |
| Sex | ||||||
| Female | 1,204,474 (53.6%) | 604,118 (55%) | 350,063 (51.9%) | 250,293 (53%) | 350,063 / 600,356 (58.3%) | 604,118 / 1,204,474 (50.2%) |
| Male | 1,040,789 (46.4%) | 494,611 (45%) | 324,476 (48.1%) | 221,702 (47%) | 324,476 / 546,178 (59.4%) | 494,611 / 1,040,789 (47.5%) |
| Age | ||||||
| 1–34 | 994,161 (44.3%) | 480,435 (43.7%) | 303,163 (44.9%) | 210,563 (44.6%) | 303,163 / 513,726 (59%) | 480,435 / 994,161 (48.3%) |
| 35–54 | 772,080 (34.4%) | 368,767 (33.6%) | 240,406 (35.6%) | 162,907 (34.5%) | 240,406 / 403,313 (59.6%) | 368,767 / 772,080 (47.8%) |
| 55–69 | 339,862 (15.1%) | 163,879 (14.9%) | 102,141 (15.1%) | 73,842 (15.6%) | 102,141 / 175,983 (58%) | 163,879 / 339,862 (48.2%) |
| 70–84 | 96,653 (4.3%) | 52,607 (4.8%) | 23,587 (3.5%) | 20,459 (4.3%) | 23,587 / 44,046 (53.6%) | 52,607 / 96,653 (54.4%) |
| 85 and older | 42,507 (1.9%) | 33,041 (3%) | 5,242 (0.8%) | 4,224 (0.9%) | 5,242 / 9,466 (55.4%) | 33,041 / 42,507 (77.7%) |
| Place of residence | ||||||
| Residential | 2,103,186 (93.7%) | 997,801 (90.8%) | 650,403 (96.4%) | 454,982 (96.4%) | 650,403 / 1,105,385 (58.8%) | 997,801 / 2,103,186 (47.4%) |
| Care/Nursing home | 69,653 (3.1%) | 61,238 (5.6%) | 4,569 (0.7%) | 3,846 (0.8%) | 4,569 / 8,415 (54.3%) | 61,238 / 69,653 (87.9%) |
| Other/Unknown | 72,424 (3.2%) | 39,690 (3.6%) | 19,567 (2.9%) | 13,167 (2.8%) | 19,567 / 32,734 (59.8%) | 39,690 / 72,424 (54.8%) |
| Ethnicity | ||||||
| White | 1,661,317 (74%) | 801,261 (72.9%) | 498,491 (73.9%) | 361,565 (76.6%) | 498,491 / 860,056 (58%) | 801,261 / 1,661,317 (48.2%) |
| Asian | 304,239 (13.6%) | 141,753 (12.9%) | 93,538 (13.9%) | 68,948 (14.6%) | 93,538 / 162,486 (57.6%) | 141,753 / 304,239 (46.6%) |
| Black | 104,222 (4.6%) | 59,641 (5.4%) | 31,018 (4.6%) | 13,563 (2.9%) | 31,018 / 44,581 (69.6%) | 59,641 / 104,222 (57.2%) |
| Other/Mixed/Unknown | 175,485 (7.8%) | 96,074 (8.7%) | 51,492 (7.6%) | 27,919 (5.9%) | 51,492 / 79,411 (64.8%) | 96,074 / 175,485 (54.7%) |
| IMD decile | ||||||
| 1-2 (most deprived) | 511,627 (22.8%) | 220,159 (20%) | 157,151 (23.3%) | 134,317 (28.5%) | 157,151 / 291,468 (53.9%) | 220,159 / 511,627 (43%) |
| 3-4 | 518,743 (23.1%) | 262,880 (23.9%) | 154,287 (22.9%) | 101,576 (21.5%) | 154,287 / 255,863 (60.3%) | 262,880 / 518,743 (50.7%) |
| 5-6 | 449,578 (20%) | 232,880 (21.2%) | 132,750 (19.7%) | 83,948 (17.8%) | 132,750 / 216,698 (61.3%) | 232,880 / 449,578 (51.8%) |
| 7-8 | 405,967 (18.1%) | 203,710 (18.5%) | 120,260 (17.8%) | 81,997 (17.4%) | 120,260 / 202,257 (59.5%) | 203,710 / 405,967 (50.2%) |
| 9-10 | 359,348 (16%) | 179,100 (16.3%) | 110,091 (16.3%) | 70,157 (14.9%) | 110,091 / 180,248 (61.1%) | 179,100 / 359,348 (49.8%) |
| NHS England region | ||||||
| East of England | 278,518 (12.4%) | 180,053 (16.4%) | 76,352 (11.3%) | 22,113 (4.7%) | 76,352 / 98,465 (77.5%) | 180,053 / 278,518 (64.6%) |
| London | 506,242 (22.5%) | 305,857 (27.8%) | 151,081 (22.4%) | 49,304 (10.4%) | 151,081 / 200,385 (75.4%) | 305,857 / 506,242 (60.4%) |
| Midlands | 426,468 (19%) | 203,450 (18.5%) | 109,281 (16.2%) | 113,737 (24.1%) | 109,281 / 223,018 (49%) | 203,450 / 426,468 (47.7%) |
| North East and Yorkshire | 276,566 (12.3%) | 58,991 (5.4%) | 89,615 (13.3%) | 127,960 (27.1%) | 89,615 / 217,575 (41.2%) | 58,991 / 276,566 (21.3%) |
| North West | 268,856 (12%) | 56,906 (5.2%) | 106,257 (15.8%) | 105,693 (22.4%) | 106,257 / 211,950 (50.1%) | 56,906 / 268,856 (21.2%) |
| South East | 356,046 (15.9%) | 199,190 (18.1%) | 121,190 (18%) | 35,666 (7.6%) | 121,190 / 156,856 (77.3%) | 199,190 / 356,046 (55.9%) |
| South West | 132,567 (5.9%) | 94,282 (8.6%) | 20,763 (3.1%) | 17,522 (3.7%) | 20,763 / 38,285 (54.2%) | 94,282 / 132,567 (71.1%) |
| Specimen date | ||||||
| 1 Nov-21 Nov | 348,521 (15.5%) | 119,271 (10.9%) | 13,288 (2%) | 215,962 (45.8%) | 13,288 / 229,250 (5.8%) | 119,271 / 348,521 (34.2%) |
| 22 Nov-12 Dec | 237,937 (10.6%) | 86,881 (7.9%) | 44,857 (6.7%) | 106,199 (22.5%) | 44,857 / 151,056 (29.7%) | 86,881 / 237,937 (36.5%) |
| 13 Dec-2 Jan | 660,572 (29.4%) | 355,297 (32.3%) | 214,439 (31.8%) | 90,836 (19.2%) | 214,439 / 305,275 (70.2%) | 355,297 / 660,572 (53.8%) |
| 3 Jan-23 Jan | 710,152 (31.6%) | 386,329 (35.2%) | 272,576 (40.4%) | 51,247 (10.9%) | 272,576 / 323,823 (84.2%) | 386,329 / 710,152 (54.4%) |
| 24 Jan-14 Feb | 288,081 (12.8%) | 150,951 (13.7%) | 129,379 (19.2%) | 7,751 (1.6%) | 129,379 / 137,130 (94.3%) | 150,951 / 288,081 (52.4%) |
ALL, n (%); Missing, n (%); SGTF, n with SGTF (%) in subset of tests with non-missing SGTF status; Non-SGTF, n with non-SGTF (%) in subset of tests with non-missing SGTF status; SGTF prevalence, n with SGTF/total (%) in subset with known SGTF status; Missingness, n with missing SGTF status/total (%).